期刊文献+

冠状动脉粥样硬化病变演变的研究进展 被引量:5

下载PDF
导出
摘要 冠状动脉粥样硬化病变在形态学上表现为局灶性和偏心性,在病理学上表现为异质性[1]。虽然目前有关冠状动脉粥样硬化病变发生、进展和不稳定的病理生理及发病机制的研究仍在不断深入,但是对其演进确切机制的了解仍然极为有限[2]。另外,冠状动脉粥样硬化并非是一个不断进展而无法逆转的疾病,其病程也并非随着年龄的增长而不断延伸。事实上,动脉粥样硬化病变有着自身的演化规律并维持着动态的平衡,在一定的条件下粥样病变斑块进展会减慢、停止甚至发生斑块消退。因此,更深入地了解动脉粥样硬化病变演进的机制,认识动脉硬化病变进展和消退之间的动态平衡规律,有助于人们更好地干预病变的进展并促进粥样斑块的消退。
出处 《中国循证心血管医学杂志》 2013年第6期661-663,共3页 Chinese Journal of Evidence-Based Cardiovascular Medicine
  • 相关文献

参考文献3

二级参考文献34

  • 1Steven E. Nissen,Stephen J. Nicholls,Ilks Sipahi,Peter Libby,Joel S. Raichlen,Christie M. Ballantyne,Jean Davignon,Raimund Erbel,Jean Charles Fruchart,Jean-Claude Tardif,Paul Schoenhagen,Tim Crowe,Valerie Cain,Kathy Wolski,Marlene Coormastic,E. Murat Tuzcu,仝其广(译),王淑敏(译),胡大一(校).极高强度他汀治疗对冠状动脉粥样硬化消退的影响——ASTEROID试验[J].美国医学会杂志(中文版),2006,25(4):215-223. 被引量:346
  • 2Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350:1495-1504.
  • 3LaRosa JC, Grundy SM, Waters DD, et al; Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352:1425-1435.
  • 4Pedersen TR, Faergeman O, Kastelein J J, et al; Incremental Decrease in End Points Through Aggressive Lipid Lowedng (IDEAL) Study Group. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study:a randomized controlled trial. JAMA. 2005;294:2437-2445.
  • 5Grundy SM, Cleeman JI, Merz CN, et al; Coordinating Committee of the National Cholesterol Education Program. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel Ⅲ Guidelines. J Am Coll Cardiol. 2004;44:720-732.
  • 6Blankenhom DH, Azen SP, Kramsch DM, et al;MARS Research Group. Coronary angiographic changes with Iovastatin therapy: the Monitored Atherosclerosis Regression Study (MARS). Ann Intern Med.1993;119:969-976.
  • 7Waters D, Higginson L, Gladstone P, et al. Effects of monotherapy with HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed be serial quantitaUve arteriography: the Canadian Coronary Atherosclerosis Intervention Trial(CCAIT). Circulation. 1994;89:959-968.
  • 8Jukema JW, Bruschke AV, van Boven A J, et al. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels: the Regression Growth Evaluation Statin Study (REGRESS). Circulation. 1995;91:2528-2540.
  • 9Pitt B, Mancini GB, Ellis SG, Rosrnan HS, Park J-S,McGovem ME. Pravastatin limitaUon of atherosclerosis in the coronary arteries (PLAC Ⅰ): reduction in atherosclerosis progression and clinical events. J Am Coll Cardiol. 1995;26:1133-1139.
  • 10Brown G, Albers J J, Fisher LD, et al. Regression of coronary artery disease as a result of intensive lipidlowering therapy in men with high levels of apolipoprotein B. N Engl J Med. 1990;323:1289-1298.

共引文献412

同被引文献73

引证文献5

二级引证文献29

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部